Compass Group PLC Stock (LSE: CPG) on 26 December 2025: Vermaat Deal Lands, FY26 Guidance Targets ~10% Profit Growth, Analysts See Upside

Compass Group PLC Stock (LSE: CPG) on 26 December 2025: Vermaat Deal Lands, FY26 Guidance Targets ~10% Profit Growth, Analysts See Upside

Compass Group PLC stock is heading into the year-end lull with investors balancing two powerful forces: the steadiness of its outsourcing-driven growth engine and the reality that 2026 growth rates are expected to cool as inflation moderates.

One practical wrinkle first: London markets are shut for the Christmas/Boxing Day holidays, so there’s no fresh UK trading print for Friday, 26 December 2025. Reuters noted the London market would remain closed on Thursday and Friday for Christmas and Boxing Day. [1]

That makes the latest reliable “snapshot” the Wednesday, 24 December 2025 close—just before the lights went dim.

Compass Group share price snapshot (as of the last London close)

As of the 24 December 2025 close, Compass Group shares were around 2,370p, with the market marked “closed” on retail platforms and the stock sitting near the lower end of its 52‑week range. [2]

Key reference points investors are watching right now:

  • Previous close: ~2,370p (24 Dec) [3]
  • 52‑week range: roughly 2,314p to 2,853p [4]
  • Dividend timing (next): ex‑dividend 15 Jan 2026, pay date 26 Feb 2026 [5]

If you’re wondering why the stock feels “stuck” despite strong operational results: the market is currently pricing Compass like a high-quality compounder…but not giving it infinite credit for inflation-fueled revenue growth that’s expected to slow.

What’s the latest Compass Group news as of 26 December 2025?

Even with markets closed today, the company has had a busy December—mostly on corporate actions and governance rather than surprise trading shocks.

1) Vermaat acquisition: EU cleared it, and the deal completed

Compass’ biggest-ever deal of 2025—buying premium European foodservice player Vermaat—moved from “strategic plan” to “done.”

  • The European Commission publicly stated it approved Compass’ acquisition of sole control of Vermaat under EU merger rules. [6]
  • Vermaat Group’s newsroom then announced the acquisition had been completed following approvals from relevant authorities (dated 16 December 2025), describing Vermaat continuing to operate on a standalone basis while leveraging Compass’ scale. [7]

Why it matters for the stock: Compass’ 2026 outlook explicitly includes M&A contributions (and Vermaat is the headline item). [8]

2) Annual Report published; AGM date confirmed

On 17 December 2025, Compass confirmed publication of its Annual Report 2025, Notice of the 2026 AGM, and proxy materials—and set the AGM for Thursday, 5 February 2026 in London. [9]

For investors, that February date is not just formalities: it’s paired with the company’s “Annual General Meeting & First Quarter Trading Update” on the same day in the firm’s calendar. [10]

3) Governance / director updates

Compass also issued a Director Declaration dated 8 December 2025 about external appointments of a non-executive director (a normal governance disclosure rather than a business shock). [11]

FY25 results: strong year, but the market is laser-focused on the 2026 slope

Compass’ most important fundamental anchor right now is its full-year FY25 performance (year ended 30 September 2025) and the company’s FY26 guidance.

From the company’s FY25 announcement:

  • Revenue:$46.1bn [12]
  • Underlying operating profit:$3,335m (with margin progress) [13]
  • Underlying operating margin:7.2% (up vs prior year) [14]
  • Underlying free cash flow: about $2.0bn with 88% conversion [15]
  • Client retention:~96%+ (Compass cited retention over 96% / 96.3%) [16]
  • New business wins:$3.8bn (annual revenue of wins in the last 12 months) [17]

Reuters’ read-through on the same result set: Compass beat expectations on profit and revenue, helped by strong U.S. workplace demand, while noting the company’s guidance broadly aligned with forecasts—a key reason shares can wobble even on “good” numbers. [18]

The FY26 guidance headline: around 10% profit growth, ~7% organic revenue growth

Compass’ own outlook for 2026 is unusually explicit for a services giant:

  • Underlying operating profit growth:around 10% (constant currency) [19]
  • Drivers it highlighted include:
    • Organic revenue growth ~7.0%
    • ~2% profit growth from M&A (including Vermaat)
    • Continued margin progression [20]

Translation: Compass is telling the market, “Yes, inflation will cool, but we still think the machine can output ~10% profit growth.”

The investor question is whether that “machine” keeps humming if office occupancy patterns change again, if wage pressure spikes, or if competitive bidding tightens.

Analyst forecasts (what the Street thinks today)

Analyst consensus is still broadly constructive—but not euphoric.

Consensus rating and price targets

Investing.com’s compiled view (as displayed on its Compass consensus page) shows:

  • 19 analysts covering the name
  • Consensus rating: “Buy” (with a distribution of buys/holds/sells)
  • Average 12‑month target: about 2,798p
  • Range: roughly 2,149p (low) to 3,167p (high) [21]

It also lists notable late‑2025 actions such as an RBC upgrade (Dec 1) and Berenberg maintain (Dec 8), among others. [22]

MarketBeat, using a smaller analyst set on its UK page, shows a higher average target near 2,979p (still in the same general “mid/high‑20s pounds” orbit). [23]

Growth expectations: “cooling, not collapsing”

A big theme in third-party commentary around Compass is that 2026 is likely to look slower than the inflation-boosted stretches—but still healthy.

  • Reuters explicitly tied the moderation narrative to lower inflation impacting revenue growth rates even as underlying demand remains supported by workplace dining and contract wins. [24]
  • Company guidance itself bakes in that moderation while still targeting strong profit growth through mix, execution, and margin. [25]

The Vermaat angle: why this deal is strategically “very Compass”

Compass is already a scale monster, especially in North America. The market opportunity for it is not “invent food”—it’s convert self-operated sites into outsourced contracts, then improve unit economics through purchasing, tech, menu engineering, and labor scheduling. That model tends to work best when:

  1. clients feel operational complexity rising, and
  2. they want a partner with systems, procurement leverage, and compliance muscle.

Vermaat adds a different flavor: premium, concept-forward European foodservice with brands and multi-sector platforms across markets including the Netherlands, Belgium, France, and Germany (as described in Vermaat’s announcement). [26]

Compass, in its FY25 materials, positioned Vermaat as part of expanding capabilities and supporting growth—explicitly including it in the 2026 M&A contribution. [27]

For investors, integration risk is real—but Compass has a long track record of bolt-ons. The more subtle question is whether premium concepts lift growth and pricing power in Europe enough to move the group needle over time.

What to watch next (near-term catalysts into early 2026)

Because today (26 Dec) is a market holiday, the next meaningful information bursts are scheduled:

  • 15 Jan 2026: Ex‑dividend date [28]
  • 5 Feb 2026:AGM + First Quarter Trading Update (same day per company calendar) [29]
  • 26 Feb 2026: Dividend pay date [30]
  • 11 May 2026: Half-year results [31]

That Q1 trading update on 5 February is the next “tell” on whether volumes (especially Business & Industry) are tracking the company’s ~7% organic growth expectation.

Risks investors keep circling (because the universe loves irony)

Even a high-quality caterer isn’t magically immune to gravity. The recurring watchouts around Compass Group stock include:

  • Volume sensitivity: if corporate footfall dips, some on-site spending softens (especially in Business & Industry).
  • Wage and food-cost inflation: Compass has pricing mechanisms, but timing gaps can pressure margins.
  • FX translation: Compass reports in USD; the share trades in GBP—currency moves can distort perceptions quarter to quarter.
  • M&A execution: Vermaat adds opportunity, but also integration complexity and near-term leverage considerations (which Compass itself flagged in its guidance commentary). [32]

Bottom line for 26 December 2025

Compass Group PLC stock ends 2025 in a very “market being the market” mood: the business is performing well, the company is guiding confidently, and analysts still see upside—yet the share price is sitting close to the lower band of its annual range, reflecting investor caution about the pace of growth as inflation eases.

The cleanest way to frame the setup:

  • Operational story: strong retention, strong wins, margin progression, and a newly completed strategic European acquisition. [33]
  • Market debate: can Compass keep compounding at a premium valuation if inflation-driven revenue tailwinds fade—without needing heroic office occupancy assumptions? [34]

Not financial advice—just the current map of the maze. The next big breadcrumb is the 5 February 2026 trading update. [35]

References

1. www.reuters.com, 2. www.hl.co.uk, 3. www.hl.co.uk, 4. www.hl.co.uk, 5. www.compass-group.com, 6. ec.europa.eu, 7. vermaatgroup.com, 8. www.compass-group.com, 9. www.investegate.co.uk, 10. www.compass-group.com, 11. www.tradingview.com, 12. www.compass-group.com, 13. www.compass-group.com, 14. www.compass-group.com, 15. www.compass-group.com, 16. www.compass-group.com, 17. www.compass-group.com, 18. www.reuters.com, 19. www.compass-group.com, 20. www.compass-group.com, 21. www.investing.com, 22. www.investing.com, 23. www.marketbeat.com, 24. www.reuters.com, 25. www.compass-group.com, 26. vermaatgroup.com, 27. www.compass-group.com, 28. www.compass-group.com, 29. www.compass-group.com, 30. www.compass-group.com, 31. www.compass-group.com, 32. www.compass-group.com, 33. www.compass-group.com, 34. www.reuters.com, 35. www.compass-group.com

Stock Market Today

  • GSK plc Stock Update: FDA Twice-Yearly Asthma Biologic, Pricing Deals, and 2026 Catalysts (Dec 26, 2025)
    December 26, 2025, 4:12 AM EST. GSK plc stock sits in a defensive, pipeline-driven phase as 2025 closes. The latest catalysts include FDA approval of Exdensur (depemokimab) for severe eosinophilic asthma with twice-yearly dosing, a sign that convenience could lift adherence and broaden the franchise, though the agency did not approve it for CRSwNP. Investors are weighing this against persistent competition from Dupixent and Xolair, and the impact of a U.S. drug-pricing deal on the respiratory business. European regulatory momentum supports expanded vaccine use, adding optional growth, while Shingrix noise underscores mix dynamics. Thin holiday liquidity can exaggerate moves, but the stock story remains: regulatory approvals, pricing frameworks, and evidence that new products offset patent expiries will drive 2026 forecasts.
GSK plc Stock (NYSE: GSK, LSE: GSK): Latest News, Forecasts, and Key Catalysts as of Dec. 26, 2025
Previous Story

GSK plc Stock (NYSE: GSK, LSE: GSK): Latest News, Forecasts, and Key Catalysts as of Dec. 26, 2025

British Airways faces customer leadership vacuum as Chief Customer Officer Calum Laming set to depart in March 2026
Next Story

British Airways faces customer leadership vacuum as Chief Customer Officer Calum Laming set to depart in March 2026

Go toTop